Related Experiment Video

Updated: Aug 8, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

500

Tripterygium glycosides improve abnormal lipid deposition in nephrotic syndrome rat models

Bidan Zheng1, Dongfang Lu1, Xiuping Chen1

  • 1Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.

Renal Failure
|March 6, 2023
PubMed
Abstract

Insights

Tripterygium glycosides (TGs) reduce kidney damage and abnormal lipid deposition in nephrotic syndrome (NS) rats. This study suggests TGs may offer a new therapeutic strategy for reducing renal lipotoxicity in NS patients.

Area of Science:

  • Nephrology
  • Pharmacology
  • Biochemistry

Background:

  • Nephrotic syndrome (NS) is characterized by abnormal lipid deposition and renal injury.
  • Doxorubicin-induced nephropathy is a common model for studying NS.
  • Understanding the mechanisms of renal lipotoxicity is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the therapeutic effect of tripterygium glycosides (TGs) on regulating abnormal lipid deposition in nephrotic syndrome (NS) rats.
  • To evaluate the impact of TGs on renal injury, oxidative stress, and apoptosis in a doxorubicin-induced NS rat model.
  • To explore the molecular mechanisms underlying the protective effects of TGs.

Main Methods:

  • Nephrotic syndrome was induced in Sprague-Dawley rats using doxorubicin.
  • Rats were treated with TGs, prednisone, or water for 5 weeks.
  • Biomedical indexes, renal pathology, lipid deposition, oxidative damage, apoptosis, and protein expression were assessed.

Main Results:

  • TGs significantly improved biomedical indexes and reduced pathological changes and lipid deposition in the kidneys.
  • TGs treatment decreased renal oxidative damage and apoptosis.
  • TGs modulated the expression of key proteins involved in apoptosis and lipid metabolism, including Bcl-2, CD36, ADFP, Bax, and Cleaved caspase-3.

Conclusions:

  • Tripterygium glycosides (TGs) effectively alleviate renal injury and lipid deposition induced by doxorubicin in NS rats.
  • TGs demonstrate potential as a novel therapeutic strategy for mitigating renal lipotoxicity in NS.
  • The findings highlight the therapeutic promise of TGs in managing nephrotic syndrome.
Keywords:
Doxorubicinlipotoxicitynephrotic syndrometripterygium glycosides

More Related Videos

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.5K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

271

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
12
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
13
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
22
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
726
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
224